ARTICLE | Clinical News
Eprodisate: Development discontinued
May 10, 2010 7:00 AM UTC
Bellus discontinued its NC-503 diabetes development program after the compound missed the primary endpoint in a Phase IIa trial to treat Type II diabetes. The compound is also in Phase III testing as ...